232 related articles for article (PubMed ID: 26257010)
1. Monte Carlo method based QSAR modeling of maleimide derivatives as glycogen synthase kinase-3β inhibitors.
Živković JV; Trutić NV; Veselinović JB; Nikolić GM; Veselinović AM
Comput Biol Med; 2015 Sep; 64():276-82. PubMed ID: 26257010
[TBL] [Abstract][Full Text] [Related]
2. 3D-QSAR and molecular docking studies on 3-anilino-4-arylmaleimide derivatives as glycogen synthase kinase-3β inhibitors.
Akhtar M; Bharatam PV
Chem Biol Drug Des; 2012 Apr; 79(4):560-71. PubMed ID: 22168279
[TBL] [Abstract][Full Text] [Related]
3. Monte Carlo QSAR models for predicting organophosphate inhibition of acetycholinesterase.
Veselinović JB; Nikolić GM; Trutić NV; Živković JV; Veselinović AM
SAR QSAR Environ Res; 2015 Jun; 26(6):449-60. PubMed ID: 26043064
[TBL] [Abstract][Full Text] [Related]
4. QSAR models for HEPT derivates as NNRTI inhibitors based on Monte Carlo method.
Toropova AP; Toropov AA; Veselinović JB; Miljković FN; Veselinović AM
Eur J Med Chem; 2014 Apr; 77():298-305. PubMed ID: 24657566
[TBL] [Abstract][Full Text] [Related]
5. Use of the Monte Carlo Method for OECD Principles-Guided QSAR Modeling of SIRT1 Inhibitors.
Kumar A; Chauhan S
Arch Pharm (Weinheim); 2017 Jan; 350(1):. PubMed ID: 28025857
[TBL] [Abstract][Full Text] [Related]
6. Monte Carlo method based QSAR modelling of natural lipase inhibitors using hybrid optimal descriptors.
Kumar A; Chauhan S
SAR QSAR Environ Res; 2017 Mar; 28(3):179-197. PubMed ID: 28271914
[TBL] [Abstract][Full Text] [Related]
7. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
Dessalew N; Patel DS; Bharatam PV
J Mol Graph Model; 2007 Mar; 25(6):885-95. PubMed ID: 17018257
[TBL] [Abstract][Full Text] [Related]
8. Monte carlo method-based QSAR modeling of penicillins binding to human serum proteins.
Veselinović JB; Toropov AA; Toropova AP; Nikolić GM; Veselinović AM
Arch Pharm (Weinheim); 2015 Jan; 348(1):62-7. PubMed ID: 25408278
[TBL] [Abstract][Full Text] [Related]
9. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.
Lescot E; Bureau R; Sopkova-de Oliveira Santos J; Rochais C; Lisowski V; Lancelot JC; Rault S
J Chem Inf Model; 2005; 45(3):708-15. PubMed ID: 15921460
[TBL] [Abstract][Full Text] [Related]
10. Design and development of novel focal adhesion kinase (FAK) inhibitors using Monte Carlo method with index of ideality of correlation to validate QSAR.
Kumar P; Kumar A; Sindhu J
SAR QSAR Environ Res; 2019 Feb; 30(2):63-80. PubMed ID: 30793981
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.
Taha MO; Bustanji Y; Al-Ghussein MA; Mohammad M; Zalloum H; Al-Masri IM; Atallah N
J Med Chem; 2008 Apr; 51(7):2062-77. PubMed ID: 18324764
[TBL] [Abstract][Full Text] [Related]
12. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.
Kim KH; Gaisina I; Gallier F; Holzle D; Blond SY; Mesecar A; Kozikowski AP
J Mol Model; 2009 Dec; 15(12):1463-79. PubMed ID: 19440740
[TBL] [Abstract][Full Text] [Related]
13. Use of Simplified Molecular Input Line Entry System and molecular graph based descriptors in prediction and design of pancreatic lipase inhibitors.
Kumar A; Chauhan S
Future Med Chem; 2018 Jul; 10(13):1603-1622. PubMed ID: 30028205
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of 3-aryl-4-pyrrolyl-maleimides as glycogen synthase kinase-3β inhibitors.
Ye Q; Li M; Zhou YB; Cao JY; Xu L; Li YJ; Han L; Gao JR; Hu YZ; Li J
Arch Pharm (Weinheim); 2013 May; 346(5):349-58. PubMed ID: 23585245
[TBL] [Abstract][Full Text] [Related]
15. Development and design of novel cardiovascular therapeutics based on Rho kinase inhibition-In silico approach.
Ćirić Zdravković S; Pavlović M; Apostlović S; Koraćević G; Šalinger Martinović S; Stanojević D; Sokolović D; Veselinović AM
Comput Biol Chem; 2019 Apr; 79():55-62. PubMed ID: 30716601
[TBL] [Abstract][Full Text] [Related]
16. coral Software: QSAR for Anticancer Agents.
Benfenati E; Toropov AA; Toropova AP; Manganaro A; Gonella Diaza R
Chem Biol Drug Des; 2011 Jun; 77(6):471-6. PubMed ID: 21435183
[TBL] [Abstract][Full Text] [Related]
17. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
Fang J; Huang D; Zhao W; Ge H; Luo HB; Xu J
J Chem Inf Model; 2011 Jun; 51(6):1431-8. PubMed ID: 21615159
[TBL] [Abstract][Full Text] [Related]
18. Glycogen synthase kinase-3 inhibition by 3-anilino-4-phenylmaleimides: insights from 3D-QSAR and docking.
Prasanna S; Daga PR; Xie A; Doerksen RJ
J Comput Aided Mol Des; 2009 Feb; 23(2):113-27. PubMed ID: 18839067
[TBL] [Abstract][Full Text] [Related]
19. Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3.
Zhang HC; Boñaga LV; Ye H; Derian CK; Damiano BP; Maryanoff BE
Bioorg Med Chem Lett; 2007 May; 17(10):2863-8. PubMed ID: 17350261
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and biological evaluation of novel 7-azaindolyl-heteroaryl-maleimides as potent and selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors.
O'Neill DJ; Shen L; Prouty C; Conway BR; Westover L; Xu JZ; Zhang HC; Maryanoff BE; Murray WV; Demarest KT; Kuo GH
Bioorg Med Chem; 2004 Jun; 12(12):3167-85. PubMed ID: 15158785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
